about
Safety of human papillomavirus vaccines: a reviewAdult vaccination coverage levels among users of complementary/alternative medicine - results from the 2002 National Health Interview Survey (NHIS)Combination vaccines: postlicensure safety evaluation.Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years.Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS.Surveillance of adverse effects following vaccination and safety of immunization programs.The role of attitudes about vaccine safety, efficacy, and value in explaining parents' reported vaccination behavior.Vaccine adverse events reported during the first ten years (1998-2008) after introduction in the state of Rondonia, Brazil.The Role of Risk Perception in Flu Vaccine Behavior among African-American and White Adults in the United States.Source Credibility and the Biasing Effect of Narrative Information on the Perception of Vaccination Risks.The media-driven risk society, the anti-vaccination movement and risk of autismo.A sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvated vaccine: might it be an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder?Identifying adverse events of vaccines using a Bayesian method of medically guided information sharing.[Suspected adverse reactions after vaccination. Results from the German Health Interview and Examination Survey for Children and Adolescents. Part 2: predictors of parental reporting of suspected adverse reactions after vaccinations].Prioritizing polio.Development of vaccine risk communication messages using risk comparisons and mathematical modeling.Preparedness and response against diseases with epidemic potential in the European Union: a qualitative case study of Middle East Respiratory Syndrome (MERS) and poliomyelitis in five member states
P2860
Q28082119-EBCB42C0-035E-4345-9CAF-6869547B8303Q33320885-7D4E6537-313F-4ECD-89DE-FD26BAAE5EEEQ34440148-7B255088-2FFF-4A8A-8FF7-241909F14DD9Q37376626-0A7E5CF5-380C-4262-8527-F2532F952544Q37503234-1C9701BB-0687-4062-A5A2-5C4330D0A121Q37823382-BDA844C6-1B6D-4938-B0D3-ED024BAF4373Q39529587-0F1D1F34-77CA-4392-BE86-785C51AFBAD6Q40254074-942E45F8-0EFE-4B1A-8B9E-586943EF8E23Q40453407-444AED7D-72CB-4E3B-80F3-F0C571303F2FQ40845544-DF4E9EFF-5504-4873-82C0-54CA59260503Q41464298-63F8E3B6-5E81-4A02-9236-0750D8297689Q41666889-A55E8D20-7C04-4F36-A54A-1EF251A94B8EQ42627193-70C7F634-1441-4D96-8CD2-B161385F759AQ45178712-F9FD328B-08AA-4540-9D9B-0D066B237106Q46892437-3C782305-AFE2-44EE-ACEA-66C7C968F613Q51861247-DAAF48E5-DEAC-4387-9861-87A83B4EFEB3Q56395477-B37F6F2E-CF01-4956-B2E9-43C6046D6FF5
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Vaccine risks: real, perceived and unknown.
@ast
Vaccine risks: real, perceived and unknown.
@en
type
label
Vaccine risks: real, perceived and unknown.
@ast
Vaccine risks: real, perceived and unknown.
@en
prefLabel
Vaccine risks: real, perceived and unknown.
@ast
Vaccine risks: real, perceived and unknown.
@en
P1433
P1476
Vaccine risks: real, perceived and unknown.
@en
P2093
P356
10.1016/S0264-410X(99)00292-3
P407
P478
17 Suppl 3
P577
1999-10-01T00:00:00Z